Abstract
AbstractTreatment with neutralizing monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contributes to COVID-19 management. Unfortunately, SARS-CoV-2 variants can escape several of these recently approved mAbs, highlighting the need for additional discovery and development. In a convalescent COVID-19 patient, we identified six mAbs, classified in four epitope groups, that potently neutralized SARS-CoV-2 Wuhan, alpha, beta, gamma and delta infection in vitro. In hamsters, mAbs 3E6 and 3B8 potently cured infection with SARS-CoV-2 Wuhan, beta and delta when administered post-viral infection at 5 mg/kg. Even at 0.2 mg/kg, 3B8 still reduced viral titers. Intramuscular delivery of DNA-encoded 3B8 resulted in in vivo mAb production of median serum levels up to 90 μg/ml, and protected hamsters against delta infection. Overall, our data mark 3B8 as a promising candidate against COVID-19, and highlight advances in both the identification and gene-based delivery of potent human mAbs.
Publisher
Cold Spring Harbor Laboratory
Reference59 articles.
1. Ritchie, H. et al. Coronavirus Pandemic (COVID-19). https://ourworldindata.org/coronavirus (2021).
2. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
3. Neutralizing monoclonal antibodies for treatment of COVID-19;Nat. Rev. Immunol,2021
4. Unknown. The Antibody Society: COVID-19 Biologics Tracker. https://www.antibodysociety.org/covid-19-biologics-tracker/ (2021).